UMMS Affiliation
Department of Medicine, Division of Hospital Medicine
Publication Date
2020-04-14
Document Type
Article Postprint
Disciplines
Cardiology | Cardiovascular Diseases | Infectious Disease | Virus Diseases
Abstract
We read with much interest the article “Are certain drugs associated with enhanced mortality in COVID -19” by Goldstein et al your esteemed Journal. Authors have discussed the theoretical basis of angiotensin receptor blockers, statins in worsening outcome of COVID – 19 patients.(1) We believe that this topic is rapidly evolving and requires further evidence and discussion for understanding the multiple factors which contribute to the pathogenesis and outcome. We have the following comments.
Keywords
cardiac drugs, COVID-19, coronavirus, mortality, angiotensin receptor blockers, pathogenesis, letter to the editor
Rights and Permissions
© The Author(s) 2020. Published by Oxford University Press on behalf of the Association of Physicians. Accepted manuscript posted after 12 months as allowed by publisher's self-archiving policy at https://academic.oup.com/journals/pages/self_archiving_policy_b
DOI of Published Version
10.1093/qjmed/hcaa127
Source
Mishra AK, Sahu KK, Sargent J. Cardiac drugs and outcome in COVID - 19. QJM. 2020 Apr 14:hcaa127. doi: 10.1093/qjmed/hcaa127. Epub ahead of print. PMID: 32289168. Link to article on publisher's site
Journal/Book/Conference Title
QJM : monthly journal of the Association of Physicians
Related Resources
PubMed ID
32289168
Repository Citation
Mishra AK, Sahu KK, Sargent JB. (2020). Cardiac drugs and outcome in COVID-19. COVID-19 Publications by UMMS Authors. https://doi.org/10.1093/qjmed/hcaa127. Retrieved from https://escholarship.umassmed.edu/covid19/10
Included in
Cardiology Commons, Cardiovascular Diseases Commons, Infectious Disease Commons, Virus Diseases Commons